Drug intelligence / Profile preview

aspirin + atorvastatin

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral
01

Overview

Aspirin + atorvastatin is a fixed-dose combination of two small molecule drugs used primarily for the prevention of cardiovascular events such as heart attack and stroke. Aspirin acts as an antiplatelet agent by irreversibly inhibiting cyclooxygenase-1 (COX-1), thereby reducing thromboxane A2 production and preventing platelet aggregation. Atorvastatin is a statin that inhibits HMG-CoA reductase to lower cholesterol synthesis in the liver; it reduces low-density lipoprotein (LDL) cholesterol and triglycerides while increasing high-density lipoprotein (HDL) cholesterol. The combination provides additive benefits in reducing vascular inflammation and improving endothelial function beyond monotherapy with either agent alone. It is indicated for patients at high risk of cardiovascular disease or those who have undergone procedures such as coronary artery bypass grafting[4][5][8].

Brand names
Ecosprin AVAztor AspAtorva AspModlip ASGMactor ASPAtorlip-ASPAtorec-ASPLipikind-ASLipicure-ASTonact-ASP
Other names
atorvastatin + aspirin
02

Targets

HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on aspirin + atorvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aspirin + atorvastatin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call